ATC code J05 Antivirals for systemic use is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup J05 is part of the anatomical group J Antiinfectives for systemic use.
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QJ05. National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
J05A Direct acting antiviral drugs
J05AA Thiosemicarbazones
J05AA01 MetisazoneJ05AB Nucleosides and nucleotides excluding reverse transcriptase inhibitors
J05AB01 Aciclovir J05AB02 Idoxuridine J05AB03 Vidarabine J05AB06 Ganciclovir J05AB09 Famciclovir J05AB11 Valaciclovir J05AB12 Cidofovir J05AB13 Penciclovir J05AB14 Valganciclovir J05AB15 Brivudine J05AB16 Remdesivir J05AB17 Brincidofovir J05AB18 MolnupiravirJ05AC Cyclic amines
J05AC02 Rimantadine J05AC03 TromantadineJ05AD Phosphonic acid derivatives
J05AD01 Foscarnet J05AD02 FosfonetJ05AE Protease inhibitors
J05AE01 Saquinavir J05AE02 Indinavir J05AE03 Ritonavir J05AE04 Nelfinavir J05AE05 Amprenavir J05AE07 Fosamprenavir J05AE08 Atazanavir J05AE09 Tipranavir J05AE10 Darunavir J05AE11 Ensitrelvir J05AE30 Nirmatrelvir and ritonavirJ05AF Nucleoside and nucleotide reverse-transcriptase inhibitors
J05AF01 Zidovudine J05AF02 Didanosine J05AF03 Zalcitabine J05AF04 Stavudine J05AF05 Lamivudine J05AF06 Abacavir J05AF07 Tenofovir disoproxil J05AF08 Adefovir dipivoxil J05AF09 Emtricitabine J05AF10 Entecavir J05AF11 Telbivudine J05AF12 Clevudine J05AF13 Tenofovir alafenamideJ05AG Non-nucleoside reverse-transcriptase inhibitors
J05AG01 Nevirapine J05AG02 Delavirdine J05AG03 Efavirenz J05AG04 Etravirine J05AG05 Rilpivirine J05AG06 Doravirine J05AG07 ElsulfavirineJ05AH Neuraminidase inhibitors
J05AH01 Zanamivir J05AH02 Oseltamivir J05AH03 Peramivir J05AH04 LaninamivirJ05AJ Integrase inhibitors
J05AJ01 Raltegravir J05AJ02 Elvitegravir J05AJ03 Dolutegravir J05AJ04 CabotegravirJ05AP Antivirals for treatment of HCV infections
J05AP01 Ribavirin J05AP02 Telaprevir J05AP03 Boceprevir J05AP04 Faldaprevir J05AP05 Simeprevir J05AP06 Asunaprevir J05AP07 Daclatasvir J05AP08 Sofosbuvir J05AP09 Dasabuvir J05AP10 Elbasvir J05AP11 Grazoprevir J05AP12 Coblopasvir J05AP13 Ravidasvir J05AP14 Narlaprevir J05AP51 Sofosbuvir and ledipasvir J05AP52 Dasabuvir, ombitasvir, paritaprevir and ritonavir J05AP53 Ombitasvir, paritaprevir and ritonavir J05AP54 Elbasvir and grazoprevir J05AP55 Sofosbuvir and velpatasvir J05AP56 Sofosbuvir, velpatasvir and voxilaprevir J05AP57 Glecaprevir and pibrentasvir J05AP58 Daclatasvir, asunaprevir and beclabuvirJ05AR Antivirals for treatment of HIV infections, combinations
J05AR01 Zidovudine and lamivudine J05AR02 Lamivudine and abacavir J05AR03 Tenofovir disoproxil and emtricitabine J05AR04 Zidovudine, lamivudine and abacavir J05AR05 Zidovudine, lamivudine and nevirapine J05AR06 Emtricitabine, tenofovir disoproxil and efavirenz J05AR07 Stavudine, lamivudine and nevirapine J05AR08 Emtricitabine, tenofovir disoproxil and rilpivirine J05AR09 Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat J05AR10 Lopinavir and ritonavir J05AR11 Lamivudine, tenofovir disoproxil and efavirenz J05AR12 Lamivudine and tenofovir disoproxil J05AR13 Lamivudine, abacavir and dolutegravir J05AR14 Darunavir and cobicistat J05AR15 Atazanavir and cobicistat J05AR16 Lamivudine and raltegravir J05AR17 Emtricitabine and tenofovir alafenamide J05AR18 Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat J05AR19 Emtricitabine, tenofovir alafenamide and rilpivirine J05AR20 Emtricitabine, tenofovir alafenamide and bictegravir J05AR21 Dolutegravir and rilpivirine J05AR22 Emtricitabine, tenofovir alafenamide, darunavir and cobicistat J05AR23 Atazanavir and ritonavir J05AR24 Lamivudine, tenofovir disoproxil and doravirine J05AR25 Lamivudine and dolutegravir J05AR26 Darunavir and ritonavir J05AR27 Lamivudine, tenofovir disoproxil and dolutegravir J05AR28 Stavudine and lamivudine J05AR29 Emtricitabine, tenofovir alafenamide and dolutegravirJ05AX Other antivirals
J05AX01 Moroxydine J05AX02 Lysozyme J05AX05 Inosine pranobex J05AX06 Pleconaril J05AX07 Enfuvirtide J05AX09 Maraviroc J05AX10 Maribavir J05AX12 Dolutegravir J05AX13 Umifenovir J05AX17 Enisamium iodide J05AX18 Letermovir J05AX19 Tilorone J05AX21 Pentanedioic acid imidazolyl ethanamide J05AX23 Ibalizumab J05AX24 Tecovirimat J05AX25 Baloxavir marboxil J05AX26 Amenamevir J05AX27 Favipiravir J05AX28 Bulevirtide J05AX29 Fostemsavir J05AX31 Lenacapavir J05AX32 Riamilovir J05AX33 LabuvirtideReferences
"ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020. https://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/ATC/index.html ↩
World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022. /wiki/World_Health_Organization ↩
"Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022. https://www.whocc.no/atc/structure_and_principles/ ↩
"ATC/DDD Index 2022: code J05". WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc_ddd_index/?code=J05 ↩
"ATCvet Index 2022: code QJ05". WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcvet/atcvet_index/?code=J05 ↩